Abstract
Introduction

Angiogenesis is of critical importance to tumour development and metastasis. When a tumour grows to a certain volume, new blood vessels sprouting from established vessels are formed to supply the tumour in excess nutrients and remove waste
. It has been established that the degree of neovascularization is well correlated with tumour malignancy and is thus one of the key criteria for grading tumours in patients [2, 3] . The angiogenic switch is well controlled and triggered by pro-angiogenic factors. Vascular endothelial growth factor (VEGF) is the most potent and specific mitogen for stimulating cascades of angiogenesis in endothelial cells [4] . The tyrosine kinase receptor VEGFR2 is the main receptor that is responsible for mediating the promotion of angiogenesis both in embryogenesis and adulthood pathological conditions [5, 6] . The fact that tumour vasculature exhibits an up-regulated VEGFR2 expression makes VEGFR2 a hot potential target for antiangiogenic therapy in recent years [7, 8] . VEGFR2 is mainly expressed on the surface of activated non-quiescent endothelial cells [9] , and this characteristic makes it a suitable target for molecular magnetic resonance imaging (mMRI) . [10] . This has brought a demand for early and accurate means of defining the [11, 12] . Winter et al. detected ␣v␤3 integrin overexpression in a rabbit tumour model by using Gadolinium (Gd)-containing nanoparticles coupled to a ␣v␤3 peptidomimetic antagonist [13] . Backer [14] . However [15] . We also measured the overexpression of c-Met in vivo by using an anti-c-Met mAb conjugated to albumin-(Gd-DTPA)-biotin in C6 rat gliomas, and by using streptavidinsuper paramagnetic iron oxide in a hepatocarcinogenesis model [16, 17] . Albumin-(Gd-DTPA) is one of the new-emerging macromolecular contrast media used in dynamic contrast-enhanced MRI, which produces differential enhancement by leaking through the junctions of hyper-permeable endothelial cells in tumour but not in normal tissue [18] . In this study, the probe VEGFR2-albumin-(Gd-DTPA)-biotin successfully targeted extracellular VEGFR2 on angiogenic endothelial cells, and was able to assess the heterogeneous characteristics of VEGFR2 expression associated with angiogenesis during glioma progression. This method may provide valuable information for the evaluation of tumour angiogenesis.
The outcome of human malignant gliomas (especially glioblastoma multiforme, GBM) is very poor, despite traditional clinical therapies. GBM, the most common type of glioma, is characterized by a high-degree of vascularization
et al. demonstrated increased binding to VEGFR2 in xenografted breast tumours as compared to VEGFR2-receptorblocked mice by using near infrared imaging with VEGF linked to a dendrimer
Materials and methods
Intracerebral glioma cell injection
A C6 glioma cell implantation protocol was created by modification of the method described by N. Kobayashi et al. [19] , and previously published by our group [15] [20] .
Immunohistochemistry
The 
Synthesis of anti-VEGFR2 MRI agent
The contrast agent, biotin-BSA (bovine serum albumin)-Gd-DTPA, was prepared based on the modification of the method developed by Dafni et al. [21] . The detailed methodology is referenced as described by Towner et al. [16] . [24] . In brief, five images were collected for each experimental condition, and the mean fluorescence intensity of [15] [16] [17] [18] [19] [20] ROIs per image was integrated using the EZ-C1 software (Nikon). Co-localization analysis was done using a Imaris Coloc module (Imaris vs. 6.4) , and data were presented as percentage co-localization and the Manders co-localization coefficient [25] . Figure 1A shows an enhanced VEGFR2 expression in C6 gliomas, compared to no band for VEGFR2 expression in normal brain by Western blotting. In the immunohistochemistry staining for VEGFR2 in C6 gliomas and contralateral normal brain, VEGFR2 is strongly expressed in microvessels among dense glioma cells (Fig.1B-iv) , and also on the endothelial cells lining around the big blood vessels (Fig. 1B-v) .
Statistical analyses
Results
In vitro assessment of VEGFR2 expression by Western blotting and immunohistochemistry
In vivo detection and quantification of VEGFR2 expression
As illustrated by Fig. 2 (Fig. 3A, B-iii) was obtained which was the subtraction between the T1 images of pre- (Fig. 3A, B-i ) and 2 hrs after (Fig. 3A, B-ii) (Fig. 4B) .
injection of the contrast agent. In the rats injected with the control-IgG contrast agent, there was not much difference after injection up to 2 hrs in the tumour region as showed in Fig. 3A-iii (data not shown for timepoints prior to 2 hrs). This indicates that almost none or very little of the control probe was taken up by the tumour tissue, or remained after 2 hrs. However, significant changes occurred in the rats injected with anti-VEGFR2 probe. Figure 3B-ii shows a
Fig. 1 VEGFR2 overexpression in C6 rat gliomas. (A) Western blotting of VEGFR2 from normal brain and C6 gliomas. ␤-actin is used as loading control. (B) Immunohistochemical localizations of VEGFR2 (20ϫ magnification) in normal brain tissue (B-i), tumour boundary (B-ii) and PT (B-iv) shows glioma cells; (B-v) shows cross-section of a vessel). Representative T2-weighted image (B-iii) was taken at day 24. dramatic increase in MR signal intensity in parts of the tumour region 2 hrs after injection, and this change was clearly depicted in the difference image (Fig. 3B-iii). Strong anti-VEGFR2 probe uptake indicates strong VEGFR2 expression in the tumour regions. Figure 3A, B-iv shows a corresponding T2-weighted image taken before the injection. Using a combination of both difference images and T2-weighted images, we defined four groups of ROIs as PT, PN, TI and N. The necrotic area was depicted as a dark region in T2 images with little uptake of the anti-VEGFR2 probe as shown in a difference image. For the regions where the probe was bound, there were different increases in signal intensities in different glioma region. Two hours following injection of the VEGFR2 probe, PT and PN regions had the most significant MR signal intensity increases (12-fold for PT and 10-fold for PN, compared to the contralateral brain tissue, whereas the TI region was only 2.3-fold compared to the contralateral region; Fig. 4A). There were minimal changes in signal intensity in either all brain regions in the control-IgG injected rats, or within the contralateral brain tissue in the VEGFR2 targeted rats. The signal intensities changed dynamically during 2 hrs' MRI observation. For instance, signal intensity in the PT region kept increasing significantly from 20 min. after injection of the VEGFR2 probe, compared to the PT region in control-IgG injected rats
Fluorescence staining at 2 hrs after administration of the probe confirmed that the distribution of VEGFR2 probe was higher in the tumour region. In all fluorescence images the VEGFR2 probe was stained red with streptavidin-Cy3, which bound to the biotin moiety of the probe. Figure 5 showed a high intensity for the VEGFR2 probe in the tumour region (obtained from the glioma periphery region) (Fig. 5D) , and the mean fluorescence intensity of probe in the tumour region was found to be significantly higher than that measured in contralateral brain tissue or glioma tissue from a control-IgG injected rat (Fig. 5F) .
The differentiation of VEGFR2 expression in different glioma regions was confirmed in Fig. 6B . The probe was seen to be distributed mainly in PT and PN regions (Fig. 6B-ii and iv) (Fig. 6D-i-iii) , indicating that the distribution of the VEGFR2 probe was not associated with infiltrated leucocytes in the glioma tissue. (Fig. 7A) . The regional blood volume in the rectangular region, which encompassed blood vessels that supplied the tumour, was calculated and found to increase correspondingly with an increase in tumour volumes (Fig. 7C) . As shown in Fig. 7B Figure 7E shows the co-registration of the 3D vasculature with VEGFR2 expression (as shown in the MR contrast difference image, and also shown in Fig. 3B-iii 
87% (with a thresholded Mander's coefficient of 0.4342) for co-localization of the VEGFR2 probe (red) and laminin (green), a marker for endothelial cells. Furthermore, the fluorescence staining of CD45, a common antigen found on leucocytes, showed that the VEGFR2 probe (red) was poorly co-localized with CD45 (blue)
Visualization of vasculature associated with VEGFR2 expression and changes of CBV
The blood of the frontal cortex, where the tumour is located, is supplied by the middle cerebral artery. A representative 2D MR angiogram was overlaid onto a T2-weighted tumour morphological MR image
Discussion
Non-invasive mMRI is a key component of molecular imaging which developed mainly over the last decade [26] . Using mMRI to monitor tumour angiogenesis is beneficial in the early diagnosis, and accurate grading of a tumour, and for the development of anti-angiogenic drug therapy [27, 28] . VEGF/VEGFR has been well demonstrated as a critical signalling pathway in the development of tumour angiogenesis [29, 30] . Figure 4 . [32] [33] [34] . Our study demonstrated Fig. 3 . [26, 38] , mMRI has a great advantage as a nonradionuclide-based imaging modality. With the use of a high magnetic field (7 Tesla ) and a highly specific mAb which is bound to the albumin-Gd based contrast agent, our study overcame the major disadvantage of mMRI for its inherent low sensitivity [26] Fig. 3B-iii) .
Mainly two high-affinity receptors for VEGF are involved in angiogenesis, VEGFR1 (flt-1), which is a negative regulator, whereas VEGFR2 (flk-1) is a positive regulator. Millauer et al. have demonstrated that
Fig. 3 T1 weighted MR images obtained before and 2 hrs after injection of control IgG (A-i and -ii) and VEGFR2-mAb (B-i and -ii) -linked mMRI agents, with corresponding difference images (iii) and T2-weighted images obtained before injection of the contrast agent (iv). Representatives of ROIs in each group are depicted as circles, using for calculating signal intensities and probe concentrations in
Signal intensity increases are measured between 2 hrs after and before administration of control-IgG or VEGFR2-mAb linked mMRI agents. (B) Dynamic changes of signal intensity increase percentages in PT and N area after injection of the contrast agents (significance is made by PT area between VEGFR2-mAb and control-IgG group). Three ROIs were calculated in each particular region (PT, PN, TI and N). The data were shown as mean Ϯ S.D. Significant differences were obtained (using a Student's t-test) if
interest for using this method to target VEGFR2 to assess anti-angiogenic therapy.
